An Australian concrete product maker has settled a lawsuit brought by US industrial equipment manufacturer Illinois Tool Works over its patents for precast concrete products.
US cryptocurrency maker Ripple Labs has hit back at an intellectual property lawsuit brought by the Australian company behind the ubiquitous PayID mobile banking system, saying its PayID trade mark is neither substantially identical nor deceptively similar to the Aussie mark.
US drug company Merck Sharp & Dohme has settled trade mark litigation brought by German drug maker Merck KGaA alleging it violated a 1970 agreement by using the “Merck” mark in Australia.
A court has issued an order restraining US blockchain company Ripple Labs from advertising its PayID system to Aussies, two days after the company agreed to geoblock its website within Australia.
US industrial equipment manufacturer Illinois Tool Works has launched Federal Court patent infringement proceedings against an Australian producer of precast concrete products.
US blockchain technology firm Ripple Labs has said that it will rebrand and block access to allegedly infringing websites as it seeks to rapidly resolve an intellectual property dispute launched over the PayID trade mark.
The company behind the ubiquitous mobile banking PayID system has filed Federal Court trade mark proceedings against a US blockchain technology firm over its global real-time payment service.
Drug manufacturer Janssen wants to expand its high stakes case against Juno Pharmaceuticals over its HIV drug Prezista, alleging Juno’s plans to launch a generic version of the drug threaten another one of its patents.
Ariosa Diagnostics is fighting to revoke a patent for noninvasive prenatal test owned by Sequenom, arguing it merely describes how to extract “incorporeal” genetic information that is naturally found within the DNA of an unborn foetus.
Drug maker Janssen has fired off a lawsuit against Juno Pharmaceuticals for allegedly threatening to infringe a patent for its HIV drug Prezista with a generic version of the drug, one year after fending off generic competition from a different drug maker.